Metastatic Breast Cancer Clinical Trials

A listing of 65 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Breast Cancer

1 - 12 of 65

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 65 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Autism participants are Texas, California, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy volunteer trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Healthy Volunteers

Learn More

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626

Recruiting

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main quest... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/19/2024

Locations: Mayo Clinic - Phoenix, Phoenix, Arizona +134 locations

Mayo Clinic - Phoenix, Phoenix, Arizona

University of Arizona - Cancer Center, Tucson, Arizona

California Research Institute, Los Angeles, California

Providence Medical Foundation - Santa Rosa, CA, Santa Rosa, California

Boca Raton Regional Hospital, Boca Raton, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Miami Cancer Institute Plantation, Plantation, Florida

Emory University School of Medicine, Atlanta, Georgia

Norton Cancer Institute, Louisville, Kentucky

Hematology Oncology Clinic, Baton Rouge, Louisiana

Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan

Allina Health System DBA Virginia Piper Cancer Institute, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Saint Luke's Cancer Institute, Kansas City, Missouri

Washington University School of Medicine, Saint Louis, Missouri

University of Nebraska Medical Center, Omaha, Nebraska

Renown Regional Medical Centre, Reno, Nevada

New Jersey Cancer Care, PA, Belleville, New Jersey

Icahn School of Medicine at Mount Sinai, New York, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

Altru Health Systems, Grand Forks, North Dakota

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James), Columbus, Ohio

Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Lyndon B. Johnson Hospital, Houston, Texas

Baylor College of Medicine, Houston, Texas

MD Anderson Cancer Center, Houston, Texas

Harris Health System - Smith Clinic, Houston, Texas

University of Vermont Medical Center, Burlington, Vermont

Blacktown Hospital, Blacktown, Not set

Concord Repatriation General Hospital, Concord, Not set

Mater Misericordiae Ltd, South Brisbane, South Brisbane, Not set

Cliniques Universitaires Saint-Luc, Brussels, Not set

Antwerp University Hospital (UZA), Edegem, Not set

Universitaire Ziekenhuizen Leuven, Leuven, Not set

Clinique CHC MontLégia, Liège, Not set

CHU UCL Namur - Site De Sainte-Elisabeth, Namur, Not set

The Ottawa General Hospital, Ottawa, Ontario

Sunnybrook Health Sciences Centre -Bayview Campus, Toronto, Ontario

Hospital Maisonneuve-Rosemont, Montréal, Quebec

Lady Davis Institute for Medical Research Jewish General Hospital, Montréal, Quebec

Masarykuv onkologicky ustav, Brno, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

Fakultni nemocnice Olomouc - Oncology clinic, Olomouc, Not set

Fakultní nemocnice v Motole, Praha 5, Not set

Service d'Oncologie Medicale - CHRU Besancon, Besançon, Not set

Institut Bergonie, Bordeaux, Not set

Centre Francois Baclesse, CAEN Cedex 05, Not set

Centre Oscar Lambret, Lille, Not set

Centre Leon Berard, Lyon, Not set

Institut Paoli-Calmettes, Marseille, Not set

CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC), Poitiers, Not set

Centre Henri Becquerel, Rouen, Not set

Institut de cancerologie Strasbourg Europe (ICANS), Strasbourg, Not set

Institut Claudius Regaud, Toulouse, Not set

Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Universitaetsklinikum Ulm, Ulm, Not set

Budapesti Uzsoki Utcai Korhaz, Budapest, Not set

Rambam Health Care Campus, Haifa, Not set

Hadassah Ein-Karem Medical Center, Jerusalem, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Rabin MC, Petach Tikva, Not set

Kaplan Medical Center, Reẖovot, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv, Not set

Sheba Medical Center, Tel HaShomer, Not set

Centro Riferimento Oncologico - Aviano, Aviano, Not set

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l., Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

Humanitas Istituto Clinico Catanese, Misterbianco, Not set

Azienda Ospedaliero-Universitaria di Modena, Modena, Not set

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Not set

Azienda Ospedaliero Universitaria di Parma, Parma, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Not set

Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento, Verona, Not set

National Cancer Center, Gyeonggi-do, Not set

Chonnam National University Hwasun Hospital, Hwasun, Not set

Asan Medical Center, Seoul, Not set

Korea University Anam Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej, Biała Podlaska, Not set

Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdańsk, Not set

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii, Gliwice, Not set

Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Onkologii Klinicznej, Kielce, Not set

Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym, Krakow, Not set

SP ZOZ Szpital Uniwersytecki w Krakowie, Oddzial Onkologii Klinicznej, Kraków, Not set

NeuroMed, Lublin, Not set

Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center, Poznań, Not set

Mazowiecki Szpital Onkologiczny, Wieliszew, Not set

Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii, Łódź, Not set

Centrul Medical Focus, Bucharest, Not set

Filantropia Clinical Hospital, Bucharest, Not set

Radiotherapy Center Cluj, Cluj-Napoca, Not set

Onco Clinic Consult SA, Craiova, Not set

Oncology Center Sfantul Nectarie, Craiova, Not set

Gral Medical SRL, Piteşti, Not set

OncoMed Oncology Center, Timişoara, Not set

National Cancer Centre Singapore, Singapore, Not set

Curie Oncology, Singapore, Not set

Hospital Clinic Barcelona, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

Hospital Universitario Reina Sofia, Córdoba, Not set

Clinica Universidad de Navarra - Madrid, Madrid, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario de La Princesa, Madrid, Not set

Hospital Regional Universitario de Malaga, Málaga, Not set

Clinica Universidad de Navarra - Pamplona, Pamplona, Not set

Instituto Valenciano de Oncologia, Valencia, Not set

Changhua Christian Hospital (CCH), Changhua, Not set

Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH), Kaohsiung, Not set

National Cheng Kung University Hospital, Tainan, Not set

Tri-Service General Hospital, Taipei City, Not set

Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set

National Taiwan University Hospital, Taipei, Not set

Linkou Chang Gung Memorial Hospital (CGMHLK), Taoyuan City, Not set

Trakya University Medical Faculty, Merkez, Edirne

Kocaeli University Faculty of Medicine, İzmit, Kocaeli

Ankara University Medical Faculty Medical Oncology Department, Ankara, Not set

Uludag University Medical Faculty, Bursa, Not set

Liv Hospital Ankara, Cankaya, Not set

Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Not set

Medical Point Izmir Hospital, İzmir, Not set

Suat Seren Training and Research Hospital, İzmir, Not set

West Middlesex University Hospital, Isleworth, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Nottingham City Hospital, Nottingham, Not set

Lancashire Teaching Hospitals, Preston, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer

NCT05573126

Recruiting

The aim of this study is to identify the optimal dose for EP0062 as monotherapy and to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Gender:

Female

Ages:

18 years and above

Trial Updated:

04/18/2024

Locations: Yale School of Medicine, New Haven, Connecticut +13 locations

Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239

Recruiting

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/17/2024

Locations: Banner Health MD Anderson AZ, Gilbert, Arizona +102 locations

Banner Health MD Anderson AZ, Gilbert, Arizona

Disney Family Cancer Center, Burbank, California

Lawrence J. Ellison Institute for Transformative Medicine, Los Angeles, California

Georgetown Uni Hospital; 4-N Main Hospital, Washington, District of Columbia

Medstar Research Institute, Hyattsville, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Hackensack University Medical Center, Hackensack, New Jersey

Hightower Clinical, Oklahoma City, Oklahoma

Lumi Research, Kingwood, Texas

Kadlec Clinic Hematology and Oncology, Kennewick, Washington

Swedish Medical Center, Seattle, Washington

Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Not set

Centro Oncologico Korben; Oncology, Ciudad Autonoma Buenos Aires, Not set

Instituto de Oncología de Rosario, Rosario, Not set

Hospital Provincial del Centenario, Rosario, Not set

CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, Not set

Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales

Gosford Hospital; Cancer Care Services, Gosford, New South Wales

University of the Sunshine Coast, Sippy Downs, Queensland

Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia

Cliniques Universitaires St-Luc, Bruxelles, Not set

GHdC Site Notre Dame, Charleroi, Not set

Jessa Zkh (Campus Virga Jesse), Hasselt, Not set

Clinique Ste-Elisabeth, Namur, Not set

Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO

Hospital do Cancer de Pernambuco - HCP, Recife, PE

Hospital do Câncer de Londrina, Londrina, PR

Hospital de Amor Amazônia, Porto Velho, RO

Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS

Hospital Sao Lucas - PUCRS, Porto Alegre, RS

Hospital de Cancer de Barretos, Barretos, SP

Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP

Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP

Tom Baker Cancer Centre; Dept of Pathology, Calgary, Alberta

The Moncton Hospital, Moncton, New Brunswick

Jewish General Hospital, Montreal, Quebec

Hôpital du Sacré-Coeur de Montreal, Montreal, Quebec

Hopital du Saint Sacrement, Quebec City, Quebec

Allan Blair Cancer Center, Regina, Saskatchewan

Affiliated Hospital of Hebei University; Department of medical oncology, Baoding, Not set

Beijing Cancer Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun City, Not set

Sichuan Provincial Cancer Hospital, Chengdu, Not set

Sichuan Provincial People's Hospital, Chengdu, Not set

Fujian Cancer Hospital, Fuzhou, Not set

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, Not set

Zhejiang Cancer Hospital; Breast Surgery, Hangzhou City, Not set

Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy, Harbin, Not set

Shandong Cancer Hospital, Jinan, Not set

The First Affiliated Hospital to Henan University of Science and Technology, Luoyang City, Not set

The Second Affiliated Hospital to Nanchang University, Nanchang, Not set

Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, Not set

Shantou Center Hospital, Shantou City, Not set

Tianjin Cancer Hospital; Department of Breast Oncology, Tianjin, Not set

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, Not set

Hubei Cancer Hospital, Wuhan, Not set

Clinica De La Costa, Barranquilla, Not set

Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Bogota, D.C., Not set

Oncomedica S.A., Monteria, Not set

Tampere University Hospital; Dept of Oncology, Tampere, Not set

Turku Uni Central Hospital; Oncology Clinics, Turku, Not set

Klinikum St. Marien; Frauenklinik, Amberg, Not set

Gynonco Düsseldorf, MVZ Medical Center GmbH, Düsseldorf, Not set

Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, Not set

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Not set

Caritas Klinik St. Theresia -Frauenklinik Brustzentrum, Saarbruecken, Not set

Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher, Stralsund, Not set

Queen Mary Hospital; Dept. of Clinical Oncology, Hong Kong, Not set

Ospedale San Gerardo; Centro Di Ricerca di Fase I ? Piano 8 ? Settore C, Monza, Lombardia

Casa di Cura La Maddalena; Oncologia Medica, Palermo, Sicilia

National Cancer Center, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Gangnam Severance Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul St Mary's Hospital, Seoul, Not set

Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Not set

Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii, Koszalin, Not set

National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Not set

National Cancer Centre; Medical Oncology, Singapore, Not set

Icon Cancer Centre Farrer Park, Singapore, Not set

Tan Tock Seng Hospital; Oncology, Singapore, Not set

Hopelands Cancer Centre, Hilton, Not set

Charlotte Maxeke Academic Hospital, Johannesburg, Not set

Medical Oncology Centre of Rosebank; Oncology, Johannesburg, Not set

Limpopo Cancer Research Institute, Polokwane, Not set

Chris Hani Baragwanath Clinical Trial Site, Soweto, Not set

Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, A Coruña, LA Coruña

Hospital Universitari Dexeus - Grupo Quironsalud; Servicio de Oncologia Medica, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Not set

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Not set

Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Not set

Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Not set

Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Not set

National Taiwan Uni Hospital; General Surgery, Taipei, Not set

Tri-Service General Hospital; Department of Haematology and Oncology, Taipei, Not set

Chang Gung Memorial Hospital-Linkou; Dept of Oncology, Taoyuan County, Not set

Medipol Mega Üniversite Hastanesi Göztepe, Istanbul, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Nottingham City Hospital; Oncology, Nottingham, Not set

Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

NCT05243641

Recruiting

This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer. Researchers also want to find the highest tolerable dose of the combination therapy of capmatinib and neritinib that can be used in this study drug combinations. The safety of this drug combination and the CELsignia MP test methodology will also be studied.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/16/2024

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Metastatic Breast Cancer, Breast Cancer

Learn More ›

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

NCT05596409

Recruiting

The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/15/2024

Locations: Highlands Oncology Group, PA, Springdale, Arkansas +21 locations

Conditions: Metastatic Breast Cancer

Learn More ›

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

NCT04872166

Recruiting

This is a multicenter, open label, nonrandomized, sequential dose escalation/cohort expansion, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 in subjects with advanced solid tumors and breast cancer. The study will be done in two phases, described below. Phase 1a (Dose Escalation Phase): The Phase 1a portion is designed to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/11/2024

Locations: Florida Cancer Specialists, Lake Mary, Florida +4 locations

Conditions: Advanced Solid Tumor, Metastatic Breast Cancer

Learn More ›

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738

Recruiting

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/10/2024

Locations: Clinical Trial Site, Fountain Valley, California +43 locations

Clinical Trial Site, Fountain Valley, California

Clinical Trial Site, Los Angeles, California

Clinical Trial Site, Grand Junction, Colorado

Clinical Trial Site, Danbury, Connecticut

Clinical Trial Site, Margate, Florida

Clinical Trial Site, Orlando, Florida

Clinical Trial Site, Urbana, Illinois

Clinical Trial Site, Farmington, New Mexico

Clinical Trial Site, Port Jefferson Station, New York

Clinical Trial Site, Toledo, Ohio

Clinical Trial Site, Spokane, Washington

Clinical Trial Site, Buenos Aires, Not set

Clinical Trial Site, Gosford, New South Wales

Clinical Trial Site, Westmead, New South Wales

Clinical Trial Site, Adelaide, South Australia

Clinical Trial Site, Ballarat Central, Victoria

Clinical Trial Site, Clayton, Victoria

Clinical Trial Site, Shepparton, Victoria

Clinical Trial Site, Nedlands, Western Australia

Clinical Trial Site, Central, Not set

Clinical Trial Site, Kowloon, Not set

Clinical Trial Site, Suwon-si, Gyeonggi-do

Clinical Trial Site, Busan, Not set

Clinical Trial Site, Seoul, Not set

Clinical Trial Site, Suwon, Not set

Clinical Trial Site, Kota Bharu, Kelantan

Clinical Trial Site, George Town, Penang

Clinical Trial Site, Ipoh, Perak

Clinical Trial Site, Putrajaya, Putramya

Clinical Trial Site, Kuching, Sarawak

Clinical Trial Site, Petaling Jaya, Selangor

Clinical Trial Site, Kuala Lumpur, WP

Clinical Trial Site, Changhua, Not set

Clinical Trial Site, Kaohsiung, Not set

Clinical Trial Site, Taichung, Not set

Clinical Trial Site, Tainan City, Not set

Clinical Trial Site, Taipei, Not set

Clinical Trial Site, Bangkok, Not set

Clinical Trial Site, Samut Sakhon, Not set

Clinical Trial Site, Songkhla, Not set

Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma

Learn More ›

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337

Recruiting

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/09/2024

Locations: Natera, Inc. (Data and Specimen Analysis Only), San Carlos, California +11 locations

Conditions: Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma

Learn More ›

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

NCT05563220

Recruiting

This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/04/2024

Locations: Dothan Hematology and Oncology, Dothan, Alabama +38 locations

Dothan Hematology and Oncology, Dothan, Alabama

Mayo Clinic - Arizona, Phoenix, Arizona

Highlands Oncology Group, Springdale, Arkansas

OPN Healthcare (Arcadia Location), Arcadia, California

Glendale Adventist, Glendale, California

OPN Healthcare (Los Alamitos Location), Los Alamitos, California

Cedars Sinai, Los Angeles, California

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

TOI Clinical Research, Whittier, California

Rocky Mountain Cancer Centers, Lone Tree, Colorado

Yale School Of Medicine - Smilow Cancer Hospital - Breast Center, New Haven, Connecticut

George Washington Cancer Center, Washington, District of Columbia

Advent Health (Florida Hospital) - Altamonte Springs, Altamonte Springs, Florida

Mayo Clinic - Jacksonville, Jacksonville, Florida

Ocala Oncology, Ocala, Florida

Northwestern Feinberg Scholl of Medicine Prentice Women's Hospital, Chicago, Illinois

MD Alliance for Multispecialty Research, LLC, Merriam, Kansas

New England Cancer Specialists, Scarborough, Maine

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Minnesota Oncology Hematology, Minneapolis, Minnesota

Mayo Clinic - Rochester, Rochester, Minnesota

Washington University School of Medicine in St. Louis, Saint Louis, Missouri

Astera Cancer Care, East Brunswick, New Jersey

Summit Medical Group, Florham Park, New Jersey

NYU Langone Health, New York, New York

New York Cancer and Blood Specialists, Port Jefferson Station, New York

W&IH of RI Breast Health Center of Women and Infants Hospital of Rhode Island, Providence, Rhode Island

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas

MD Anderson Cancer Center Texas, Houston, Texas

UT Health San Antonio, San Antonio, Texas

Inova Schar Cancer Institute, Fairfax, Virginia

Virginia Cancer Specialists, Fairfax, Virginia

Virginia Oncology Associates, Norfolk, Virginia

Cancer Care Northwest, Spokane Valley, Washington

Northwest Medical Specialties (Nwms) - Puyallup - Medical Oncology (Rainier Hematology-Oncology)/Exigent Research Network; LLC, Tacoma, Washington

University of WI - Carbone Cancer Center (Phase II only), Madison, Wisconsin

Conditions: Breast Cancer, Metastatic Breast Cancer

Learn More ›

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984

Recruiting

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/02/2024

Locations: Ocala Oncology Center PL DBA Florida Cancer Affiliates, Ocala, Florida +19 locations

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer

Learn More ›

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Recruiting

This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/02/2024

Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +7 locations

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer

Learn More ›

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

NCT05693766

Recruiting

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Gender:

All

Ages:

18 years and above

Trial Updated:

03/19/2024

Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer

Learn More ›

1 - 12 of 65